Detalhe da pesquisa
1.
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.
Lancet Haematol;
11(6): e436-e447, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38710185
2.
Efficacy and Safety of Donidalorsen for Hereditary Angioedema.
N Engl J Med;
2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38819395
3.
Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus.
J Allergy Clin Immunol;
2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38670233
4.
A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema.
J Allergy Clin Immunol Pract;
12(6): 1614-1621, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38609017
5.
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet;
401(10382): 1079-1090, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36868261
6.
New medications to mitigate attacks of hereditary angioedema: does one size fit all?
Lancet;
401(10375): 413-415, 2023 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36774145
7.
Prodromes predict attacks of hereditary angioedema: Results of a prospective study.
Allergy;
78(2): 577-579, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36259763
8.
The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.
World Allergy Organ J;
15(3): 100627, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35497649
9.
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet;
399(10328): 945-955, 2022 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35219377
10.
Prodromes as predictors of hereditary angioedema attacks.
Allergy;
77(4): 1309-1312, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35000208
11.
The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update.
Allergy;
77(7): 1961-1990, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35006617
12.
Correction to: Mitigating Disparity in Healthcare Resources Between Countries for Management of Hereditary Angioedema.
Clin Rev Allergy Immunol;
61(1): 98-100, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34196910
13.
Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study.
Clin Transl Allergy;
11(4): e12035, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34161665
14.
Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema.
Clin Rev Allergy Immunol;
61(1): 84-97, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34003432
15.
Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema.
Pediatr Allergy Immunol;
32(6): 1392-1396, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33851451
16.
New Instrument for the Evaluation of Prodromes and Attacks of Hereditary Angioedema (HAE-EPA).
Clin Rev Allergy Immunol;
61(1): 29-39, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33538950
17.
The Enigma of Prodromes in Hereditary Angioedema (HAE).
Clin Rev Allergy Immunol;
61(1): 15-28, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33534063
18.
Biomarkers in Hereditary Angioedema.
Clin Rev Allergy Immunol;
60(3): 404-415, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33560480
19.
Effects of Continuous Plasma-Derived Subcutaneous C1-Esterase Inhibitor on Coagulation and Fibrinolytic Parameters.
Thromb Haemost;
121(5): 690-693, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33202446
20.
Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema.
Pediatr Allergy Immunol Pulmonol;
33(3): 136-141, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32953229